All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-06-07T11:22:57.000Z

EHA2023 abstracts: What’s hot in ALL?

To help navigate the exciting content being presented at the EHA2023 Congress, the ALL Hub Steering Committee have provided their recommendations for the top abstracts to look out for in ALL.

Frontline and emerging therapies for ALL

S112 The effect of immunoglobulin prophylaxis on infectious morbidity in pediatric patients with acute lymphoblastic leukemia: results of a randomized controlled trial
S116 Donor-derived CD5 CAR T cells for T-cell acute lymphoblastic leukemia
S117 Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly-diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: ALLIANCE A041703
S118 A chemotherapy-free combination of ponatinib and blinatumomab for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: subgroup analysis from a phase II study
P329 High immunoproteasome activity as novel indicator for sensitivity to bortezomib-containing chemotherapy in acute lymphoblastic leukemia patients from Children’s Oncology Group trial AALL1231
P355 Favorable outcome of Philadelphia-positive acute lymphoblastic leukemia with imatinib, dose-reduced induction followed by allogeneic stem cell transplantation –results from the GMALL trial 08/13
P358 Hyper-CVAD with blinatumomab and inotuzumab ozogamicin for patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia: a phase II study
P364 A phase II study of low-intensity chemotherapy (mini-hyper-CVD) and ponatinib followed by blinatumomab and ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
P365 Sequential blinatumomab with reduced intensity chemotherapy for older adults with newly diagnosed Ph- B-precursor acute lymphoblastic leukemia – final results of the ALLG ALL08 study
P373 Updates from a phase II trial of mini-hyper-CVD-inotuzumab with or without blinatumomab in older patients with newly diagnosed Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia
P376 Veno-occlusive disease risk and other outcomes in patients with B-cell precursor acute lymphoblastic leukemia receiving inotuzumab ozogamicin and proceeding to hematopoietic stem cell transplantation
P390 Allo-HSCT or chemotherapy for B-cell acute lymphoblastic leukemia in the first complete remission: Impact of MRD and IKZF1
P394 Frontline combination of olverembatinib and PDT-ALL-2016 pediatric inspired protocol in Philadelphia chromosome-positive acute lymphoblastic leukemia
P397 IKZF1 alterations have a negative impact on early molecular response and survival of adult patients with B-cell precursor acute lymphoblastic leukemia treated with GMALL 07/2003 protocol in Czechia

Treatment for relapsed/refractory ALL

S113 Impact of IKZF1 deletion in relapsed and/or refractory B-cell acute lymphoblastic leukemia treated with CD19-chimeric antigen receptor T-cell therapy
S115 Consolidation with blinatumomab improves overall and relapse-free survival in patients with newly diagnosed B-cell acute lymphoblastic leukemia: impact of age and MRD level in ECOG-ACRIN E1910
S119 Combination of mini-hyper-CVD and inotuzumab (INO) followed by blinatumomab (BLINA) consolidation in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): A phase II trial
S312 Is brexucabtagene autoleucel a cost-effective treatment for refractory/relapsed acute lymphoblastic leukemia? A pharmacoeconomic analysis in the perspective of the public healthcare system.
P336 Predictive scores for relapse and progression disease in pediatric acute lymphoblastic leukemia patients based on optical genome mapping technology
P348 Genomic characterization of relapsed/refractory B-cell acute lymphoblastic leukemia pediatric patients undergoing CAR-T treatment in a single center
P362 Outcomes in patients with relapsed or refractory acute lymphoblastic leukemia receiving hematopoietic cell transplantation using real-world data from HARMONY
P363 A phase II study of flumatinib with chemotherapy for newly diagnosed Ph/BCR-ABL1-positive acute lymphoblastic leukemia in adults: updated results from RJ-ALL2020.2A trial
P367 Long-term outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3 by age, prior therapies, and subsequent transplant
P370 Efficacy and safety of the third-generation TKI olverembatinib in adults Ph/BCR-ABL1-positive acute lymphoblastic leukemia with T315I mutation and relapsed/refractory disease
P377 A phase II trial of mini-hyper-CVD with venetoclax for patients with relapsed/refractory (R/R) Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL)
P379 Ponatinib and blinatumomab in relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia or chronic myeloid leukemia in lymphoid blast phase: subgroup analysis from a phase II trial
P501 Isatuximab plus chemotherapy for pediatric relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia (ISAKIDS): Interim efficacy analysis

Biomarkers and biology

Real-world evidence

EHA 2023 abstracts

To download this document, click below.

Download here

More about...

Newsletter

Subscribe to get the best content related to ALL delivered to your inbox